A retrospective study to evaluate Radiographic characteristics and poor prognostic factors of interstitial lung disease (ILD) in nivolumab-treated patients with non-small cell lung cancer
Latest Information Update: 29 Apr 2021
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 Apr 2021 Results assessing treatment of ILD in nivolumab treated patients with NSCLC in Japan, published in the Cancer Science
- 01 Apr 2021 Results published in the Cancer Science
- 15 Feb 2020 New trial record